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Abstract
The scientific community is focused on developing antiviral therapies to mitigate the impacts
of the ongoing novel coronavirus disease 2019 (COVID-19) outbreak. This will be facilitated
by improved understanding of viral dynamics within infected hosts. Here, using a mathemat-
ical model in combination with published viral load data, we compare within-host viral
dynamics of SARS-CoV-2 with analogous dynamics of MERS-CoV and SARS-CoV. Our
quantitative analyses using a mathematical model revealed that the within-host reproduction
number at symptom onset of SARS-CoV-2 was statistically significantly larger than that of
MERS-CoV and similar to that of SARS-CoV. In addition, the time from symptom onset to
the viral load peak for SARS-CoV-2 infection was shorter than those of MERS-CoV and
SARS-CoV. These findings suggest the difficulty of controlling SARS-CoV-2 infection by
antivirals. We further used the viral dynamics model to predict the efficacy of potential antivi-
ral drugs that have different modes of action. The efficacy was measured by the reduction in
the viral load area under the curve (AUC). Our results indicate that therapies that block de
novo infection or virus production are likely to be effective if and only if initiated before the
viral load peak (which appears 2–3 days after symptom onset), but therapies that promote
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cytotoxicity of infected cells are likely to have effects with less sensitivity to the timing of
treatment initiation. Furthermore, combining a therapy that promotes cytotoxicity and one
that blocks de novo infection or virus production synergistically reduces the AUC with early
treatment. Our unique modeling approach provides insights into the pathogenesis of SARS-
CoV-2 and may be useful for development of antiviral therapies.
Introduction
The ongoing coronavirus disease 2019 (COVID-19) outbreak was first reported in Wuhan,
China, in late December 2019 [1,2]. Since then, the causative agent, SARS-CoV-2 (severe acute
respiratory syndrome coronavirus 2), has been transmitted elsewhere in China and to most
other countries and territories around the world. The number of global confirmed cases cur-
rently stands at more than 103 million (as of 3 February 2021). Given that 40%–45% of patients
are asymptomatic [3], and even symptomatic infections are underreported [4], the true num-
ber of cases is most likely much higher than this.
Antiviral drugs and vaccines are currently under development to counter this outbreak.
The efficacy of these drugs can be evaluated in vitro using a cell culture system supporting
SARS-CoV-2 infection [5,6] and in various animal models [7–10].
To aid the development process, characterization of the viral dynamics of SARS-CoV-2 is
crucial. Several studies have reported longitudinal viral load data from symptomatic patients
collected for over 20 days after symptom onset [8,11–16]. Mathematical models describing
viral dynamics have been used to analyze such data [17–20]. In a recent paper [9], the patho-
geneses of SARS-CoV-2, MERS-CoV, and SARS-CoV infections were compared in a nonhu-
man primate model. Here, we analyze and compare longitudinal viral load data of SARS-CoV-
2, SARS-CoV, and MERS-CoV in humans. Further, we fit a mathematical model to the viral
load data and then use the model with best-fit parameters to predict the effect of potential anti-
viral treatments on viral dynamics. We do not consider treatments, such as dexamethasone,
aimed at reducing the inflammatory response or other downstream events that can lead to the
generation of symptoms. The results of our antiviral treatment simulations provide informa-
tion useful for the development of antiviral agents and treatment strategies for SARS-CoV-2,
specifically addressing questions such as the best time to initiate a therapy given its mode of
action. Interestingly, we find that the ideal timing varies depending on the viral–host process
targeted by the antiviral drug.
Results/Discussion
Characterizing SARS-CoV-2, MERS-CoV, and SARS-CoV infections by
analyzing viral load measurements
We analyzed longitudinal SARS-CoV-2 viral load data reported in [11–14], MERS-CoV viral
load data reported in [21,22], and SARS-CoV viral load data reported in [23] using a viral
dynamic model (see Methods). Further details about the data sources are described in S1 Text
and summarized in S1 Table. A nonlinear mixed-effect modeling approach was employed in
which we fit the model to all of the patient data simultaneously to estimate parameters (see
Methods). The estimated population parameters are listed in Table 1, and estimated individual
parameters for each patient are listed in S2 Table. Comparing population parameters between
SARS-CoV-2 and the other 2 coronaviruses, the maximum rate constant for viral replication
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(γ) of SARS-CoV-2 was significantly larger than that of MERS-CoV (p<2.2×10−16) but similar
to that of SARS-CoV. The rate constant for virus infection (β) of SARS-CoV-2 was signifi-
cantly larger than that of both MERS-CoV and SARS-CoV (p = 1.0×10−8 and p = 1.3×10−12,
respectively). Moreover, the viral load at symptom onset (V(0)) of SARS-CoV-2 was similar to
that of SARS-CoV, but less than that of MERS-CoV (p<2.2×10−16). Based on the individual
parameters, the best-fit viral load curves for each patient are plotted along with the observed
data in S1 Fig for SARS-CoV-2, MERS-CoV, and SARS-CoV. We further calculated and com-
pared the following quantities, which are derived from the estimated parameters or available
by running the model (Table 1): the mean duration of virus production from an infected cell
(L = 1/δ); the within-host reproduction number at symptom onset (RS0 = γ/δ), which is the
average number of newly infected cells produced by a single infected cell at symptom onset (c.
f. [24]); the time from symptom onset to the viral load peak (Tp); and the critical inhibition
level (C� = 1−1/RS0) that needs to be reached by antivirals or vaccines to ensure that the viral
infection is driven to extinction [25–27].
RS0 of SARS-CoV-2 was statistically significantly larger than that of MERS-CoV
(p<2.2×10−16) and no different from that of SARS-CoV (Table 1). Further, according to our
model, SARS-CoV-2 hit its viral load peak 2.0 days after symptom onset (i.e., Tp), which is ear-
lier than MERS-CoV and SARS-CoV, which peaked at 12.2 days and 7.2 days after symptom
onset, respectively; however, the difference was statistically significant only between SARS--
CoV-2 and SARS-CoV (p = 2.24×10−6; Fig 1; Table 1).
Both the larger RS0 value of SARS-CoV-2 than that of MERS-CoV and the earlier peak in
viral load for SARS-CoV-2 than the other coronaviruses suggest that the virus more effectively
replicates and spreads within-host than MERS-CoV and SARS-CoV. In other words, treating
SARS-CoV-2 infection may require more potent therapies and therapies given earlier than for
the other coronaviruses. Further, the shorter Tp of SARS-CoV-2 suggests that treating SARS--
CoV-2 infection following symptom onset is more challenging because effective antiviral treat-
ment should be initiated before the viral peak, as we demonstrate in the next section. Given
that the mean time from symptom onset to hospitalization observed in China was 4.6 days
[28], symptom-based diagnosis combined with antiviral treatment might not be an effective
treatment strategy if treatment needs to be given in a hospital setting. In the next section, we
provide a detailed analysis of anti-SARS-CoV-2 therapy varying with the drug efficacy and
timing of treatment initiation.
Table 1. Estimated parameters (fixed effect) for SARS-CoV-2, MERS-CoV, and SARS-CoV infection.
Parameter name Symbol (unit) SARS-CoV-2 MERS-CoV SARS-CoV
Parameters in the model
Maximum rate constant for viral replication γ (day−1) 4 1.46# 4.13
Rate constant for virus infection β ((copies/ml)−1 day−1) 5.2×10−6 1.4×10−8# 4.9×10−8#
Death rate of infected cells δ (day−1)& 0.93 0.93 0.93
Viral load at symptom onset V(0) (copies/ml) 6.5×103 6.6×104 3.3×10−2#
Quantities derived from the parameters
Mean duration of virus production L (days) 1.08 1.08 1.08
Within-host reproduction number at symptom onset RS0 4.30 1.57# 4.44
Critical inhibition level C� 0.77 0.38# 0.75
Time from symptom onset to viral load peak Tp (days)$ 2.0 12.2 7.2$
#Statistically different from SARS-CoV-2 (the Wald test).
&The death rate of infected cells was assumed to be the same between the viruses in the process of model selection.
$Tp was computed from simulation, and the difference from SARS-CoV-2 was tested by the jackknife test.
https://doi.org/10.1371/journal.pbio.3001128.t001
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Evaluation of anti-SARS-CoV-2 therapies
Based on our mathematical model and estimated parameter values (Table 1), we conducted in
silico experiments of possible anti-SARS-CoV-2 therapies to investigate the expected outcomes
under hypothetical drug therapies (or vaccines) possessing different antiviral mechanisms of
action (Fig 2). Specifically, drug efficacy (30% to 100%, i.e., 0.3�ε,η,θ�1) and timing of ther-
apy initiation after symptom onset (i.e., 0�t��4 days) were varied, and their influence on out-
comes was investigated (see Methods) (Fig 2). We used reduction in the viral load area under
the curve (AUC) and the fraction of target cells that remain uninfected 4 weeks after symptom
onset as outcome measures. Without treatment, the AUC was 8.2×105 copies�day/ml, and
almost no target cells remained after the course of infection (e.g., Figs 2 and 3).
Blocking de novo infection. One of the major mechanisms of action for antivirals is
blocking de novo infection. Blocking can be induced by drugs including human neutralizing
antibodies either in convalescent plasma or given as monoclonal antibodies, viral entry inhibi-
tors, and/or antibodies raised by vaccination [5,29]. For example, a SARS-CoV-specific
human monoclonal antibody bamlanivimab has received emergency use authorization by the
US Food and Drug Administration for the treatment of SARS-CoV-2 [30].
Higher drug efficacy and earlier treatment initiation are associated with better outcomes:
According to our model the AUC was reduced by 73%—and 74% of target cells remained
uninfected after the course of infection—when treatment was initiated 1 day after symptom
onset and the antiviral effectiveness was 90% (Fig 2). Very early treatment initiation is the key
for better outcomes when using antiviral therapies.
According to our model, using a drug that blocks infection with 95% efficacy initiated 4
days after symptom onset, the AUC was reduced by only 14%, and only 2% of cells remain
Fig 1. Comparison of SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics. Expected viral load trajectories for SARS-CoV-2, MERS-CoV,
and SARS-CoV infection are shown. The solid curves give the solution of Eqs 5 and 6 using estimated parameters (the best-fit population
parameters), and the shaded regions correspond to 95% predictive intervals using the estimated parameters for each patient. The data
underlying this figure are given in S1 Data.
https://doi.org/10.1371/journal.pbio.3001128.g001
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uninfected (Fig 2A and 2D). This occurs because only a very small fraction of target cells
remain uninfected after the viral load peak. After infection abates, target cells will replenish,
but here we ignore this because we are evaluating the potential effects of therapy in preserving
them. Note that viral shedding may last longer with treatment than without treatment if the
antiviral efficacy is below 100% and initiated early. This is because substantial numbers of
uninfected target cells remain at the time of treatment initiation, and the infection is driven by
those uninfected cells but at a slower rate than without treatment.
We observed the same patterns for MERS-CoV and SARS-CoV (see S2A, S2D, S3A, and
S3D Figs), except that treatment initiated a few days after symptom onset may be efficacious.
As we observed in Fig 1, the viral load peak comes later for MERS-CoV and SARS-CoV than
for SARS-CoV-2. Thus, even if treatment is initiated at 4 days after symptom onset (which is
before viral load peak for those 2 viruses), improvement in the outcomes can be expected.
Blocking virus production. Most antiviral drugs inhibit intracellular virus replication.
Lopinavir/ritonavir (HIV protease inhibitors), remdesivir (anti–Ebola virus disease candidate),
Fig 2. Predicted outcomes under anti-SARS-CoV-2 monotherapies. (A–C) Expected viral load and uninfected target cell proportion trajectories with and without
treatment for the 3 different treatments. The black curves are without treatment. The blue curves are with treatment (efficacy is 95%) initiated at 4 days after
symptom onset. The red, green, and orange curves are with treatment initiated at 1 day after symptom onset, but with different efficacy (95%, 90%, and 50%,
respectively). The dotted vertical lines correspond to the timing of treatment initiation. (D–F) The heatmap shows the reduction in the viral load area under the
curve (AUC) with treatment compared to without treatment. The timing of treatment initiation and treatment efficacy were varied. Darker colors indicate a larger
reduction in the viral load AUC. The parameter setting used for the simulation in (A–C) is indicated by the same-colored squares in (D–F). The data underlying this
figure are given in S2 Data.
https://doi.org/10.1371/journal.pbio.3001128.g002
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and other nucleoside analogues as well as interferon have the potential to suppress SARS--
CoV-2 replication [31,32]. Similar to the findings for drugs blocking de novo infection, higher
efficacy and earlier treatment are associated with better outcomes. According to our model the
AUC was reduced by 76%, and 36% of the target cells remained uninfected after the course of
infection, when treatment was initiated at 1 day after symptom onset and the antiviral effec-
tiveness was 90% (Fig 2B and 2E).
In contrast, if treatment is started after the viral load peak, improvement in the outcomes
cannot be expected even with a 100% inhibition rate. Similar patterns were observed for
MERS-CoV and SARS-CoV (S2B, S2E, S3B, and S3E Figs). However, as 4 days after symptom
onset is still before the viral load peak for these 2 viruses, substantial improvement in the out-
comes is expected with treatment initiated 4 days after symptom onset for these 2 viruses (S2B,
S2E, S3B, and S3E Figs).
Promoting cytotoxicity. Another possible antiviral mechanism is to promote cytotoxic
effects. This could be done by stimulating adaptive immunity, including responses mediated
by cytotoxic T lymphocytes and natural killer cells, by immunotherapy or vaccination, but the
Fig 3. Predicted outcomes under anti-SARS-CoV-2 combination therapies. (A–C) Expected viral load and uninfected target cell proportion trajectories with and
without treatment for the 3 combination therapies. We assumed the same efficacies and timing of treatment initiation for the 2 combined treatments. The black
curves are without treatment. The blue curves are with treatment (efficacy is 95%) initiated at 4 days after symptom onset. The red, green, and orange curves are
with treatment initiated at 1 day after symptom onset, but with different efficacy (95%, 90%, and 50%, respectively). The dotted vertical lines correspond to the time
of treatment initiation. (D–F) The heatmap shows the reduction in the viral load area under the curve (AUC) with treatment compared to without treatment. The
time of treatment initiation and the treatment efficacy were varied. Darker colors indicate a larger reduction in the viral load AUC. The parameter setting used for
the simulation in (A–C) is indicated by the same-colored squares in (D–F). The data underlying this figure are given in S3 Data.
https://doi.org/10.1371/journal.pbio.3001128.g003
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effect would not be immediate. To be consistent with the other modes of drug action discussed
above, in which we assume the drug takes effect immediately after administration, we envision
a drug such as a viral-specific monoclonal antibody conjugated to a toxin, as used in cancer
therapy [33], or a non-neutralizing viral-specific monoclonal antibody that could induce
infected cell death by complement-mediated lysis or antibody-dependent cellular cytotoxicity.
A neutralizing antibody with these effector functions could be considered the equivalent of
combination therapy, which is discussed below. Compared with the other 2 therapeutic mech-
anisms of action (blocking de novo infection and virus production), the induction of cytotox-
icity directly removes infected cells that produce viruses, and therefore it enhances the rate of
viral load decay. After the viral peak, target cells are depleted and cytotoxicity-inducing ther-
apy leads to noticeably more rapid declines in viral load (Fig 2C).
Thus, a 50% effective cytotoxicity-promoting antiviral, which by our definition (see Meth-
ods) causes the death rate of infected cells to double, initiated at day 1 after symptom onset
results in an only slightly slower viral growth rate and an only slightly delayed time of viral
load peak, but more rapid decay in viral load, than the other 2 therapeutic modes of action
(blocking de novo infection and virus production) (Fig 2, orange curves). Moreover, cytotoxic-
ity induction initiated after the viral load peak can still reduce the AUC. A 95% effective cyto-
toxicity-promoting antiviral initiated at 4 days after symptom onset reduces the AUC by 13%;
however, only 2% of target cells remain uninfected because most of the target cells were already
infected by the viral load peak (Fig 2C and 2F, blue curves). We confirmed that much later
treatment initiation (13 days after symptom onset) with this type of antiviral still increases the
rate of viral load decay (S4A Fig).
Overall, compared with the effects of the other 2 types of antivirals, the effect of promoting
cytotoxicity on the AUC is less dependent on the magnitude of the antiviral effect and the tim-
ing of treatment initiation, although earlier treatment and more efficacy are positively associ-
ated with an increased reduction in the AUC.
We confirmed a similar pattern in the treatment effect on MERS-CoV and SARS-CoV
infection (S2C, S2F, S3C, and S3F Figs). Given that their viral load peak comes later than that
of SARS-CoV-2, treatment initiated at 4 days after symptom onset is predicted to still reduce
the AUC and save uninfected target cells (see below).
To evaluate the effect of treatment promoting cytotoxicity initiated long after the viral load
peak, we compared the effect of a 50% effective treatment initiated at 1 day and 13 days after
symptom onset on all 3 coronaviruses (S4 Fig). The therapy initiated at 1 day delayed the time
of the viral load peak particularly for MERS-CoV and SARS-CoV. When the treatment was
initiated at 13 days, which is after the viral load peak, the viral load declined rapidly compared
with treatment initiated at 1 day, because few target cells remained and thus new infection was
limited.
The analysis of the treatment effect of drugs with 3 different modes of action revealed that
the treatment strategy should be different for each type of drug. For example, using drugs that
block de novo infection or virus production can avoid substantial target cell reduction if initi-
ated before the viral load peak. Using a drug that promotes cytotoxicity is less time sensitive,
and treatment initiated after the viral peak still can reduce the AUC. These findings suggest
the possibility of a synergistic effect of combining drugs with different modes of action.
Combination therapy. In this section, we describe the effect of combining 2 different
drug therapies from among the 3 described in the section above. In general, combinations of
antiviral therapies are considered preferable when they synergistically enhance the antiviral
effects, reduce the needed individual drug dose, and reduce the side effects compared with
monotherapy [6,27,34–36]. Here, we focus on the synergistic antiviral effects on the model
outcomes (i.e., reduction in the AUC and saving target cells from infection).
PLOS BIOLOGY Quantitative comparison of SARS-CoV-2, MERS-CoV and SARS-CoV dynamics
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The 3 possible 2-drug combination therapies (i.e., blocking de novo infection and virus pro-
duction, blocking virus production and promoting cytotoxicity, and blocking de novo infec-
tion and promoting cytotoxicity, shown in Fig 3A and 3D, 3B and 3E, and 3C and 3F,
respectively) were simulated using the same assumptions as for the single drug therapies. All 3
combination therapies improved the antiviral effects compared to the corresponding mono-
therapies. As we expected, combining drugs with distinct modes of action, especially with a
drug promoting cytotoxicity being one of them, more effectively reduced the AUC and saved
target cells from infection. With monotherapy with a 50% antiviral effect initiated at 1 day
after symptom onset, the AUC was reduced by 13%, 44%, and 54% with the drugs blocking de
novo infection, blocking virus production, and promoting cytotoxicity, respectively (Fig 2D–
2F), whereas the AUC was reduced by 58% or greater under combination therapy (Fig 3D–
3F). Notably, combining a drug promoting cytotoxicity with 1 of the other 2 types of drugs
compensated for the “weakness” of each treatment: No clear effect is expected from the drugs
blocking de novo infection or virus production if initiated after the viral load peak.
From a biological point of view, promoting cytotoxicity is distinct from the other 2 mecha-
nisms. Both blocking de novo infection and blocking virus production limit ongoing de novo
infection, whereas promoting cytotoxicity enhances virus and infected cell removal indepen-
dent of target cell availability. A broadly neutralizing antibody with potent effector functions
that induced infected cell death would be a good therapeutic option as it induces 2 modes of
action in 1 molecule. Antibodies of this type are being explored for HIV [37,38]. SARS-CoV-2
neutralizing antibodies are also in clinical development, and the role of their effector functions
in providing protective activity is being examined [39]. Our analysis also implies that, if antivi-
ral drugs induce immunomodulation as a bystander effect, even if the treatment is initiated
after the viral load peak, they might be able to reduce viral load. We confirmed the same trends
for MERS-CoV and SARS-CoV (S5B, S5E, S6B, and S6E Figs).
Conclusions
To aid the development of antiviral drugs and treatment strategies for SARS-CoV-2 infection, we
characterized the viral dynamics of SARS-CoV-2 and the related viruses SARS-CoV and MERS--
CoV using a mathematical model. We further introduced the effect of antivirals with different
modes of action in the model and explored the influence of the drug efficacy and timing of treat-
ment initiation on the outcomes (viral load AUC and the fraction of target cells that remain unin-
fected). We found that RS0 is larger for SARS-CoV-2 compared with MERS-CoV, and the
difference in viral load peak timing was significantly different between SARS-CoV-2 and SARS--
CoV. Some studies suggest that the viral load peak for SARS-CoV-2 occurs before the onset of
symptoms [40,41], while other studies suggest that the viral load peak occurs within the first week
of symptom onset [14,42–44]. Although it is difficult to accurately determine whether the peak is
before or after symptom onset, since there are few viral load data available before the onset of
symptoms, an earlier viral peak for SARS-CoV-2 is consistent with recent findings [14,40–44].
The larger RS0 and earlier viral peak suggest it may be more difficult to treat SARS-CoV-2 infec-
tion than SARS-CoV and MERS-CoV with drug therapy that blocks viral production or de novo
infection, because for these types of drugs, treatment initiation before the viral load peak is impor-
tant to reduce viral load and save target cells from infection. The variations in parameter estimates
among the individuals studied do not change our results on the importance of initiating antiviral
therapy before the viral load peak (S7 Fig). The modeling of antivirals with different drug efficacies
highlighted the importance of early initiation of treatments blocking de novo infection and virus
production. In contrast, a treatment promoting cytotoxicity reduces AUC even when treatment is
initiated after the viral load peak. Due to the uniqueness of the drugs promoting cytotoxicity
PLOS BIOLOGY Quantitative comparison of SARS-CoV-2, MERS-CoV and SARS-CoV dynamics
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compared with the other 2 types of drugs, combination therapy with a drug promoting cytotoxic-
ity and 1 of the 2 other drugs more effectively reduced the AUC and saved target cells from infec-
tion because the combination compensated for the weakness of each drug.
We used the viral load AUC and the fraction of target cells remaining uninfected as outcomes
rather than the length of hospital stay, clinical improvement, severity, and mortality, which have
been more commonly used as primary outcomes in clinical studies [45–52]. However, the out-
comes should be determined on a case-by-case basis. For example, if the objective is to find or
assess the effectiveness of a lifesaving treatment, then mortality should be used as a primary out-
come. However, if the objective is to assess the effectiveness of antiviral treatment, the degree of
viral load reduction might be a primary outcome. Indeed, viral-load-related outcomes have been
used in multiple clinical studies for antivirals [15,46,53–57]. Further, viral load outcomes are par-
ticularly important for SARS-CoV-2 because many patients experience mild or no symptoms (i.e.,
asymptomatic cases) and yet are still isolated. To determine when to end isolation, it is frequently
necessary to have a negative PCR test as well as disappearance of symptoms [14]. This is sensible
as a strong association between viral load and infectiousness has been suggested [19].
Drug repurposing—reusing drugs already approved for specific purposes for other (new)
purposes—is currently the major approach for rapidly deploying antiviral drugs for SARS-CoV-2.
A number of drugs such as lopinavir and ritonavir [47,55]; chloroquine [48]; favipiravir [46];
interferon beta-1b, lopinavir/ritonavir, and ribavirin [58]; a nebulized form of interferon beta-1a
[59]; and remdesivir [49,50] have been tested in clinical studies. However, the findings from such
trials are not consistent: Some claim a significant effect, but the others do not, for the same drug.
One of the major issues is poor study design [60]. Beyond that, we suspect that in some cases the
treatment was not initiated early enough and may have yielded null findings even though the
drug is effective, as we demonstrated in silico in this study of drugs blocking de novo infection
and virus production. Indeed, the mean interval between symptom onset and hospitalization was
4.6 days during the COVID-19 epidemic in Shenzhen, China [28], which is longer than the inter-
val between symptom onset and viral load peak for SARS-CoV-2 (2 days), suggesting that therapy
is commonly started well after the viral load peak in hospitalized patients.
A limitation of our analysis is the simplicity of our mathematical model. However, this
model is flexible and extendable. For example, we did not consider heterogeneity of target
cells, and we assumed the death rate of an infected cell, δ, is constant. However, models with
multiple types of target cells could be developed, and δ can be made time-dependent as was
done in the case of HIV, where there were extensive viral load data [61,62]. Alternatively, equa-
tions can be introduced to explicitly model effector cell responses [63,64]. These approaches
could be reflected in extended versions of our model if relevant data and supporting evidence
become available. Indeed, several more complex models have been proposed to describe
SARS-CoV-2 viral dynamics [17,18]. However, these complex mathematical models yielded
similar conclusions as the simple model we employed about the need to initiate therapy early
when using a typical antiviral that blocks viral production.
Development or identification of effective antiviral drugs is urgently needed. We believe
our theoretical framework can at least partially explain why such drugs have not been identi-
fied (late treatment initiation) and could help design clinical studies and treatment strategies
by assessing their potential effect on viral-load-related outcomes.
Methods
Study data
The longitudinal viral load data were extracted from clinical studies of SARS-CoV-2 [11–14],
MERS-CoV [21,22], and SARS-CoV [23]. Only the data from individuals with 3 or more data
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points above the detection limit were included in the analysis. The data from patients who
received antiviral treatment during infection were excluded. We confirmed that ethics
approval was obtained from the ethics committee at each institution, and that written
informed consent was obtained from the patients or their next of kin in the original studies.
The data were extracted from images in those publications using the program DataThief III
(version 1.5, Bas Tummers; https://www.datathief.org). We converted cycle threshold (Ct) val-
ues reported in the above papers to viral RNA copy number values (copies/ml), where these
quantities are inversely proportional to each other [65]. The following formula was used to
convert Ct values (y) to viral RNA copies (x, in copies/ml): log10(x) = ay+b with a = −0.32 and
b = 14.11 [12]. S1 Table summarizes the data. The likelihood function accounted for censored
data (i.e., data points under the detection limits) [66].
Mathematical model
We used a simple target cell limited model to describe SARS-CoV-2, SARS-CoV, and MERS-CoV
viral dynamics [20,24,67]. Target cell limited models have proved very valuable in understanding
infection dynamics and therapy for chronic viral infections such as HIV [61,68], HCV [69], and
HBV [70] and for acute infections such as influenza [71], West Nile virus [72], Zika virus [73],
and SARS-CoV-2 [17,74,75]. Although the model does not explicitly describe immune responses,
the effects of immune responses are implicitly included in model parameters such as the infection
rate, which can be influenced by innate responses, and the death rate of infected cells, which can
be influenced by adaptive immune responses. Because of the simplicity of the model, these param-
eters can be estimated and compared among the 3 different coronaviruses. The form of the model
that we use was first introduced to model influenza infection [71] and is given by
dTðtÞ
dt
¼   bT tð ÞV tð Þ; ð1Þ
dIðtÞ
dt
¼ bT tð ÞV tð Þ   dI tð Þ; ð2Þ
dVðtÞ
dt
¼ pI tð Þ   cV tð Þ; ð3Þ
where the variables T(t), I(t), and V(t) are the number of uninfected target cells, the number of
infected target cells, and the amount of virus at time t (note: we used time after symptom onset as
the timescale), respectively. Symptom onset is defined slightly differently between papers, but it
essentially means when any coronavirus-related symptoms (fever, cough, and shortness of breath)
appear [76]. The parameters β, δ, p, and c represent the rate constant for virus infection, the death
rate of infected cells, the per cell viral production rate, and the per capita clearance rate of the
virus, respectively. Since the clearance rate of the virus is typically much larger than the death rate
of the infected cells in vivo [27,67,77], we made a quasi-steady state (QSS) assumption, dV(t)/
dt = 0, and replaced Eq 3 with V(t) = pI(t)/c. Because data on the numbers of coronavirus RNA
copies, V(t), rather than the number of infected cells, I(t), were available, I(t) = cV(t)/p was substi-






T tð ÞV tð Þ   dV tð Þ: ð4Þ
Furthermore, we replaced T(t) by the fraction of target cells remaining at time t, i.e., f(t) = T(t)/T
(0), where T(0) is the initial number of uninfected target cells. Note f(0) = 1. Accordingly, we
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obtained the following simplified mathematical model, which we employed to analyze the viral
load data in this study:
df ðtÞ
dt
¼   bf tð ÞV tð Þ; ð5Þ
dVðtÞ
dt
¼ gf tð ÞV tð Þ   dV tð Þ; ð6Þ
where γ = pβT(0)/c corresponds to the maximum viral replication rate under the assumption that
target cells are continuously depleted during the course of infection. Thus, f(t) is equal to or less
than 1 and continuously declines.
In our analyses, the variable V(t) corresponds to the viral load for SARS-CoV-2, MERS--
CoV, and SARS-CoV (copies/ml). Because all of them cause acute infection, loss of target cells
by physiological turnover can be ignored, considering the long lifespan of the target cells.
The nonlinear mixed-effect model
Nonlinear mixed-effect modeling was used to fit the model to the longitudinal viral load data.
The model includes both fixed effects (i.e., population parameters) and random effects. The
random effects represent the difference among patients. The parameter value for patient k is
Wkð¼ W�epkÞ, which is a product of a fixed effect, ϑ, and a random effect, epk : pk is assumed to
follow the normal distribution: N(0,O). This approach allows us to estimate the parameters for
patients with limited time point data, because the population parameters are estimated from
not only their data, but all the patients’ data. We used the viral type as a categorical covariate in
estimating the parameters γ, β, and V(0), which provide the lowest corrected Bayesian infor-
mation criterion (BICc). Fixed effects and random effects were estimated using the stochastic
approximation expectation-maximization algorithm and the empirical Bayes’ method, respec-
tively. The statistical differences of covariate for γ, β, and V(0) were tested by the Wald test. Fit-
ting was implemented using Monolix 2019R2 (https://www.lixoft.com) [78]. The estimated
(fixed and individual) parameters and the initial values are listed in Table 1 and S2 Table. The
viral load curve using the best-fit parameter estimates for each individual patient is shown,
along with the data, in S1 Fig. Note that the mixed model approach has been used elsewhere in
longitudinal viral load data analysis [17,73].
In silico experiments for antiviral therapies
Based on the parameterized model for each virus, we investigated the antiviral effects of drugs
with 3 different mechanisms of action—(i) blocking de novo infection, (ii) blocking virus pro-




VðsÞds) and the remaining fraction of target cells after the course of infection (i.e., f
(28)). Note that we used 28 days after symptom onset as the upper bound for observation,
because most viral load values are below the detection limit by this time and some previous
clinical studies used health conditions (e.g., mortality) at 28 days (4 weeks) as a primary out-
come [79]. In the simulation, the best-fit population parameters estimated by fitting the model
to the data were used. We varied the time of treatment initiation after symptom onset, t�, and
the antiviral efficacy values ε, η, and θ to assess the dependency of them on the outcomes.
Note that t� = 0 corresponds to therapy initiated immediately after symptom onset.
We modeled viral load dynamics under antiviral treatment with the 3 different mechanisms
of action as follows.
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Blocking de novo infection. The viral dynamics under antiviral treatment for blocking de
novo infection is modeled as follows:
df ðtÞ
dt
¼   1   εHðtÞð Þbf tð ÞV tð Þ; ð7Þ
dVðtÞ
dt
¼ 1   εHðtÞð Þgf tð ÞV tð Þ   dV tð Þ; ð8Þ
where H(t) is the Heaviside step function defined as H(t) = 0 if t<t�; otherwise, H(t) = 1. t� is
the time of treatment initiation, and ε is the treatment efficacy: 0<ε�1. ε = 1 implies de novo
infection is 100% inhibited.
Blocking virus production. The virus dynamics under treatment for blocking virus pro-
duction is modeled as follows:
dVðtÞ
dt
¼ 1   ZHðtÞð Þgf tð ÞV tð Þ   dV tð Þ; ð9Þ
where η is the treatment efficacy: 0<η�1. η = 1 indicates that virus production from infected
cells is fully inhibited. Note that the difference between blocking de novo infection and virus
production is that the drugs in the former model reduce β, whereas the drugs in this model
reduce p, in the full model, i.e., Eqs 1–3.
Promoting cytotoxicity. The virus dynamics under the antiviral treatment of promoting
cytotoxicity (or increasing the death rate of infected cells) is modeled as follows:
dVðtÞ
dt




dV tð Þ; ð10Þ
where θ is the treatment efficacy: 0<θ�1. θ = 1 indicates that the drug is 100% effective and
causes the immediate death of an infected cell. No drug is expected to be 100% effective. A
50% effective drug would cause a 2-fold increase in the death rate, and a 90% effective drug
would cause a 10-fold increase.
Combination therapy. The virus dynamics under therapies combining the 3 types of
drugs is modeled as follows:
df ðtÞ
dt
¼   1   εHðtÞð Þbf tð ÞV tð Þ; ð11Þ
dVðtÞ
dt




dV tð Þ: ð12Þ
In the simulation, we assumed any 2 therapies are combined (thus 1 of the 3 parameters is set
as 0).
Computation of L, RS0, C�, and Tp and statistical test for the difference
between viruses
Based on the estimated parameters, we calculated several quantities for each virus: the duration
of virus production (L = 1/δ), the reproduction number (RS0 = γ/δ) at symptom onset, and the
critical inhibition level (C� = 1−1/RS0). Further, the time from symptom onset to the viral load
peak (Tp) was calculated by running the model using estimated (fixed and individual) parame-
ters and the initial values. The difference in Tp was tested by the jackknife test [80,81]. To eval-
uate statistical differences for RS0 and C�, we applied the Wald test as well.
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S1 Data. Original numerical values for Fig 1.
(XLSX)
S2 Data. Original numerical values for Fig 2.
(XLSX)
S3 Data. Original numerical values for Fig 3.
(XLSX)
S4 Data. Original numerical values for S1 Fig.
(XLSX)
S5 Data. Original numerical values for S2 Fig.
(XLSX)
S6 Data. Original numerical values for S3 Fig.
(XLSX)
S7 Data. Original numerical values for S4 Fig.
(XLSX)
S8 Data. Original numerical values for S5 Fig.
(XLSX)
S9 Data. Original numerical values for S6 Fig.
(XLSX)
S10 Data. Original numerical values for S7 Fig.
(XLSX)
S1 Fig. Viral load trajectory for individual patients with SARS-CoV-2, MERS-CoV, and
SARS-CoV infection. (A–C) The estimated viral load for each individual patient (solid lines)
along with the observed data (closed dots) are depicted using the best-fit parameter estimates.
The dotted horizontal lines are the detection limits. Note that the detection limits for SARS--
CoV-2 were 68 (Singapore, Korea), 15 (China), and 33.3 (Germany) copies/ml. The detection
limits for MERS-CoV were 1,000 (Korea) and 15 (Saudi Arabia) copies/ml. The red closed
dots at the detection limit represent the data points where the virus was detected but below the
detection limit. The data underlying this figure are given in S4 Data.
(DOCX)
S2 Fig. Predicted outcomes under anti-MERS-CoV monotherapies. (A–C) Expected viral
load and uninfected target cell proportion trajectories with and without treatment for the 3 dif-
ferent treatments. The black curves are without treatment. The blue curves are with treatment
(efficacy is 95%) initiated at 16 days after symptom onset. The red and green curves are with
treatment initiated at 4 days after symptom onset, but with different efficacy (95% and 90%).
The dotted vertical lines correspond to the timing of treatment initiation. (D–F) The heatmap
shows the reduction in the viral load AUC with treatment compared to without treatment.
The timing of treatment initiation and treatment efficacy were varied. Darker colors indicate a
larger reduction in the viral load AUC. The parameter setting used for the simulation in (A–C)
is indicated by the same color in (D–F). The data underlying this figure are given in S5 Data.
(TIF)
S3 Fig. Predicted outcomes under anti-SARS-CoV monotherapies. (A–C) Expected viral
load and uninfected target cell proportion trajectories with and without treatment for the 3
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different treatments. The black curves are without treatment. The blue curves are with treat-
ment (efficacy is 95%) initiated at 16 days after symptom onset. The red and green curves are
with treatment initiated at 4 days after symptom onset, but with different efficacy (95% and
90%). The dotted vertical lines correspond to the timing of treatment initiation. (D–F) The
heatmap shows the reduction in the viral load AUC with treatment compared to without treat-
ment. The timing of treatment initiation and treatment efficacy were varied. Darker colors
indicate a larger reduction in the viral load AUC. The parameter setting used for the simula-
tion in (A–C) is indicated by the same color in (D–F). The data underlying this figure are
given in S6 Data.
(TIF)
S4 Fig. Predicted outcomes under drugs promoting cytotoxicity initiated at 1 and 13 days
after symptom onset. The dotted black curve corresponds to the viral load (top) and unin-
fected target cell proportion (bottom) trajectories without treatment promoting cytotoxicity
for the 3 coronaviruses. The blue and green curves are with treatment with 50% efficacy initi-
ated at 1 or 13 days after symptom onset. The data underlying this figure are given in S7 Data.
(TIF)
S5 Fig. Predicted outcomes under anti-MERS-CoV combination therapies. (A–C) Expected
viral load and uninfected target cell proportion trajectories with and without treatment for the
3 combination therapies. We assumed the same efficacies and timing of treatment initiation
for the 2 combined treatments. The black curves are without treatment. The blue curves are
with treatment (efficacy is 95%) initiated at 16 days after symptom onset. The red and green
curves are with treatment initiated at 4 days after symptom onset, but with different efficacy
(95% and 90%). The dotted vertical lines correspond to the timing of treatment initiation. (D–
F) The heatmap shows the reduction in the viral load AUC with treatment compared to with-
out treatment. The timing of treatment initiation and treatment efficacy were varied. Darker
colors indicate a larger reduction in the viral load AUC. The parameter setting used for the
simulation in (A–C) is indicated by the same color in (D–F). The data underlying this figure
are given in S8 Data.
(TIF)
S6 Fig. Predicted outcomes under anti-SARS-CoV combination therapies. (A–C) Expected
viral load and uninfected target cell proportion trajectories with and without treatment for the
3 combination therapies. We assumed the same efficacies and timing of treatment initiation
for the 2 combined treatments. The black curves are without treatment. The blue curves are
with treatment (efficacy is 95%) initiated at 16 days after symptom onset. The red and green
curves are with treatment initiated at 4 days after symptom onset, but with different efficacy
(95% and 90%). The dotted vertical lines correspond to the timing of treatment initiation. (D–
F) The heatmap shows the reduction in the viral load AUC with treatment compared to with-
out treatment. The timing of treatment initiation and treatment efficacy were varied. Darker
colors indicate a larger reduction in the viral load AUC. The parameter setting used for the
simulation in (A–C) is indicated by the same color in (D–F). The data underlying this figure
are given in S9 Data.
(TIF)
S7 Fig. Predicted outcomes under anti-SARS-CoV-2 monotherapies considering inter-
individual variation in parameters. Expected viral load and uninfected target cell proportion
trajectories with and without treatment for the 3 different treatments. The black curves are
without treatment. The blue and red curves are with treatment (efficacy is 95%) initiated at 1
day and at 4 days after symptom onset, respectively. The shaded regions correspond to 95%
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predictive intervals. The data underlying this figure are given in S10 Data.
(TIF)
S1 Table. Summary of the data used in our analysis.
(DOCX)
S2 Table. Estimated parameters and initial values for each patient.
(DOCX)
S1 Text. Study data.
(DOCX)
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